Physician profile
Anil Kumar
NPI 1437589009
$23,432.06
in general payments reported to CMS, 2019-2025
20 companies · $3,025 in 2025
The $3,025 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.58 · 2020: $83.23 · 2021: $90.46 · 2022: $371 · 2023: $13K · 2024: $6,951 · 2025: $3,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $1,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,131.25 |
| Food and Beverage | $1,695.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,453.27 | 2022-2025 | |
| Eisai INC. | $183.77 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $122.41 | 2020-2025 | Nuplazid |
| Argenx US, INC. | $111.01 | 2022-2025 | Vyvgart |
| Lundbeck LLC | $67.86 | 2021-2025 | Vyepti |
| Celgene Corporation | $61.59 | 2020-2023 | Zeposia |
| Livanova USA, INC. | $54.79 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $54.19 | 2019-2023 | |
| Csl Behring | $48.95 | 2022 | |
| Biogen, INC. | $42.88 | 2021 | |
| Supernus Pharmaceuticals, INC. | $31.93 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $31.25 | 2023-2024 | Austedo Xr |
| Allergan, INC. | $27.68 | 2019-2022 | |
| Averitas Pharma INC. | $26.59 | 2024 | Qutenza |
| Amgen INC. | $22.34 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $22.31 | 2022 | |
| Portola Pharmaceuticals, LLC | $21.48 | 2020 | |
| Neurocrine Biosciences, INC. | $19.51 | 2019 | |
| Acorda Therapeutics, INC | $16.09 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.